Introduction {#Sec1}
============

The production of enantiomerically pure chemicals has long been considered important in various sectors of the industry including food supplements, pharmaceuticals, cosmetics, fragrances, flavors, and other fine chemicals. In the case of drugs, the presence of an undesirable enantiomer leads to an increase in the dose required, and often also to adverse side effects, such as thalidomide (Roth [@CR93]). Many drugs are now synthesized using chiral synthons provided either by kinetic resolution of racemates, asymmetric synthesis or via the naturally occurring chiral pool (Sheldon [@CR105]). The replacement of conventional--chemical processes by sustainable biotechnological processes is one of the main current tendencies in white biotechnology and biocatalysis (Gavrilescu and Chisti [@CR23]).

(*R*)-hydroxycarboxylic acids (R-HAs) can be widely used as chiral precursors for several reasons: (i) they contain at least two functional groups: a hydroxy group and a carboxy group; (ii) the functional groups can easily be modified chemically; and (iii) a second chiral center can be introduced. The reported compounds using R-HAs as chiral building blocks comprise the macrocyclic component of the antibiotic elaiophylin (Sutter and Seebach [@CR112]), the hydroxyacyl hydrazines in visconsin, a peptide antibiotic (Hiramoto et al. [@CR35]), pharmaceuticals such as captopril and β-lactams (Ohashi and Hasegawa [@CR83], [@CR84]), and fungicides such as norpyrenophorin and vermiculin (Seuring and Seebach [@CR104]).

It has been reported that R-HAs can be obtained by hydrolysis of biotechnologically synthesized polyhydroxyalkanoates (PHAs) (see review (Chen and Wu [@CR8])). PHAs are microbial polyesters, which are accumulated as a carbon and energy storage material under particular environmental conditions such as under nitrogen limitation (Lee [@CR55]; Lenz and Marchessault [@CR63]). PHAs can be produced from renewable resources and are biodegradable and biocompatible (Lee [@CR55]; Lenz and Marchessault [@CR63]). It is not within the scope of this article to give a detailed review of PHA biosynthesis and its applications (please see (Chen [@CR7]), an excellent review on PHA). However, it is worth mentioning that despite considerable work on production of PHAs, only few commercial plants have been established in the past few decades (Chen [@CR7]). The drawbacks in commercialization of PHA production could be attributed to the high cost of production, limited microbial strains, difficulty in recovering the polymer, and the presence of impurities during industrial processing. This review mainly focuses on the production of PHA-relevant R-HAs; other types of R-HAs such as lactic acid are not included.

This article briefly reviews possible options for production of R-HAs and their potential applications as illustrated in Fig. [1](#Fig1){ref-type="fig"}. Furthermore, perspectives of the biotechnological processes for R-HA production are also discussed. Fig. 1Synthesis of R-HAs and their applications

Methods for R-HA production {#Sec2}
===========================

Organic acids constitute a key group among the building-block chemicals that can be produced by microbial processes (Sauer et al. [@CR98]). Most of them are natural products of microorganisms, or at least natural intermediates in major metabolic pathways. Because of their functional groups, organic acids are extremely useful as starting materials for the chemical industry. Although chiral hydroxycarboxylic acids (HAs) are attractive compounds with much potential, only few of these compounds are commercially available, such as (*R*)-3-hydroxybutyric acid (R-3HB). So far, only two enantiomerically pure R-HAs with more than 4 carbon atoms are available on the market: (*R*)-3-hydroxynonanoic acid (supplied by Exclusive Chemistry Ltd, Russia) and (*R*)-3-hydroxytetradecanoic acid (supplied by Wako Pure Chemical Industries Ltd, Japan). A survey of the most interesting (*R*)-3-hydroxycarboxylic acids is given in the [Electronic supplementary material](#AppESM1){ref-type="sec"}. Although the market for R-HAs is currently small, mainly due to high price and limited availability, it can be envisioned that once an economical viable microbial production process for one of these acids is established, the market for it will undoubtedly increase.

Chemical synthesis of R-HAs {#Sec3}
---------------------------

### De novo synthesis {#Sec4}

The introduction of the chiral center is the challenging step when producing enantiomerically pure R-HAs. Different approaches have been reported. Classical organic synthesis may include stereoselective oxidation through Sharpless' asymmetric epoxidation and consecutive hydroxylation or through Brown's asymmetric allylboration (Brown and Ramachandran [@CR5]). Enantiopure 3-hydroxyesters have been prepared chemically via enantioselective reduction using 3-keto esters as prochiral precursors (Noyori et al. [@CR81]). Recently, Spengler and Albericio ([@CR108]) reviewed various possible routes for asymmetric synthesis of enantiopure or enantiomerically enriched α-unsubstituted β-hydroxy acids (3-hydroxycarboxylic acids). General drawbacks of these reactions are the requirement of often expensive, chiral metal-complex catalysts, the contamination of end product with catalysts, and/or the high price of pure substrates. Vigorous reaction conditions such as high pressure, flammable reaction media, or cryogenic conditions are often needed (Brown and Ramachandran [@CR5]; Ikunaka [@CR36]), and the range of possible products is limited. Furthermore, the necessity to synthesize precursor molecules may complicate the synthetic procedure and may reduce the product yield (Nakahata et al. [@CR77]; Wang et al. [@CR124]). Another main disadvantage can be lower enantiomeric excesses (ee) compared to biochemical processes (Sheldon [@CR105]).

### Chemical degradation of PHA {#Sec5}

PHAs comprise of monomers with 3-hydroxy, 4-hydroxy, and 5-hydroxy groups. Up to date, about 140 R-HA monomers have been identified (Steinbüchel and Valentin [@CR109]; Sudesh et al. [@CR110]). The length of the side chains varies between 1 and 13 carbon atoms, and a broad range of functional groups can be present, e. g. halogens, phenoxy, acetoxy, phenyl, cyano, and epoxy groups (Steinbüchel and Valentin [@CR109]; Sudesh et al. [@CR110]). All of the monomers are enantiomerically pure and in (*R*)-configuration if they possess a chiral center. Therefore, it was reasoned that various enantiomerically pure R-HAs might be conveniently prepared by depolymerizing biosynthesized PHAs. For example, poly\[(*R*)-3-hydroxybutyrate\] (PHB) was for the first time suggested to be a source for the chiral pool about 11 years ago (Lee et al. [@CR58]).

Various enantiomerically pure R-HAs can be conveniently prepared by depolymerizing the biosynthesized PHA. A method for producing R-3HB and (*R*)-3-hydroxyvaleric acid (R-3HV) from PHB and poly\[(*R*)-3-hydroxybutyrate-*co*-(*R*)-3-hydroxyvalerate\] (PHBV) by chemical degradation has been reported (Seebach et al. [@CR101]). Lee et al. reported an efficient method for the preparation of R-3HB by acidic alcoholysis of PHB (Lee et al. [@CR59]). de Roo et al. ([@CR16]) produced the chiral medium chain length (mcl) (*R*)-3-hydroxycarboxylic acids via hydrolytic degradation of PHAs synthesized by *Pseudomonas putida*. PHAs were first degraded by acid methanolysis, and then the obtained R-HA methyl esters were distilled into several fractions. Subsequently, the methyl esters were saponified to yield the corresponding (*R*)-3-hydroxycarboxylic acids (de Roo et al. [@CR16]).

Biotransformation {#Sec6}
-----------------

Biotransformations are enzyme-catalyzed environmentally friendly, regio- and stereoselective processes (Bommarius and Riebel [@CR4]). With regard to the production of R-HAs, microorganisms have been used as biocatalysts to introduce the chiral centers.

### De novo biosynthesis {#Sec7}

3-Hydroxyvaleric acid has been prepared by the hydroxylation of valeric acid in fermentation using *Candida rugosa* (Hasegawa et al. [@CR30]), and a single enantiomer of 3HV (R-3HV) was similarly prepared using *P. putida*, *Pseudomonas fluorescens*, *Arthrobacter oxydans*, or *Arthrobacter crystallopietes* (Goodhue and Schaeffe [@CR25]). 3-Hydroxypropionic acid has been produced by fermentative conversion of carbohydrates (Gokarn et al. [@CR24]). The immobilized nitrile hydratase and amidase from *Rhodococcus* sp. were used to hydrolyze 3-hydroxypropionitrile, 3-hydroxyheptanenitrile, and 3-hydroxynonanenitrile to the corresponding 3-hydroxycarboxylic acids at yields of 63, 62, and 83%, respectively (Deraadt et al. [@CR17]); More recently, Hann et al. ([@CR29]) used a combination of nitrile hydratase and amidase activities of *Comamonas testosteroni* 5MGAM4D for the hydrolysis of 3-hydroxyalkanenitriles to 3HAs. It was found that the immobilized *C. testosteroni* 5MGAM4D in consecutive batch reactions was physically robust over 100 recycle reactions, and the enzyme activities of the immobilized cells were also very stable even after 106 days. This process is being used for the production of 100-kg quantities of 3-hydroxyvaleric acid (Hann et al. [@CR29]). However, the chirality of the obtained HAs using nitrile hydratase and amidase was not investigated. If these HAs are racemic mixtures, separation of *R* and *S* enantiomers will be needed for their application as synthons.

Several (*R*)- and (*S*)-3-hydroxyalkanoic acids have been prepared by the enzymatic reduction of the corresponding 3-ketoalkanoic acids (Lemieux and Giguere [@CR61]; Utaka et al. [@CR119]). Utaka et al. ([@CR119]) reported the production of optically active 3-hydroxy acids by asymmetric reduction of aliphatic short- to long-chain β-keto acids by fermenting baker's yeast (Sih et al. [@CR107]). 11 β-keto acids, ranging from 3-oxobutanoic to 3-oxooctanoic acids, were reduced to the corresponding optically pure β-hydroxy acids, which were isolated as methyl esters. In all cases, the *R*-hydroxy acids were obtained in ≥98% ee, except for 3-oxobutanoic acid, which was converted to the *S*-hydroxy acid with 86% ee. Inhibition of microbial fermentation was observed for medium chain length oxo acids ranging from 3-oxoundecanoic to 3-oxotetradecanoic acids, leading to no reduction of these oxo acids (Sih et al. [@CR107]; Utaka et al. [@CR119]). C6--C12 (*S*)-3-hydroxyalkanoic acids have been prepared from the corresponding trans-α,β unsaturated alkanoic acids by microbial hydration catalyzed by resting cells *Mucor* sp. (Tahara and Mitzutani [@CR113]). (*R*)-3-Hydroxyhexanoic acids (R-3HHx) and (*R*)-3-hydroxyheptanoic acid (R-3HP) have been prepared with a mutant strain of *C. rugosa* (Hasegawa et al. [@CR31]; Ohashi and Hasegawa [@CR84]).

### Enzymatic degradation of purified PHA in vitro {#Sec8}

Up to now, many extracellular PHA depolymerases (ePhaZs) have been identified and characterized (see reviews (Jendrossek and Handrick [@CR41]; Kim et al. [@CR50])). The ePhaZs partially degrade crystallized or denatured PHA, and the degradation products are typically R-HA monomers and/or dimmers (Jaeger et al. [@CR40]; Jendrossek and Handrick [@CR41]). ePhaZs have been mainly used for surface modification (Numata et al. [@CR82]), while very few studies have been dedicated to R-HA production using ePhaZs. It has been reported that thermophilic *Streptomyces* sp. MG can hydrolyze purified PHB to R-3HB (Calabia and Tokiwa [@CR6]). An added advantage with this strain is its stability at high temperature (50 °C), which would minimize contamination problems. Furthermore, downstream processing is relatively easy since the cells aggregate to form clumps after the fermentation process.

Extracellular lipases from different bacteria were tested for their ability to hydrolyze different types of polyesters to produce HAs (Jaeger et al. [@CR40]). It was found that most lipases were able to hydrolyze polyesters consisting of an omega-hydroxyalkanoic acid such as poly(6-hydroxyhexanoate) or poly(4-hydroxybutyrate). The dimeric ester of hydroxyhexanoate was the main product of enzymatic hydrolysis of polycaprolactone by *P. aeruginosa* lipase. Polyesters containing side chains in the polymer backbone such as PHB and other poly(3-hydroxyalkanoates) were not or were only slightly hydrolyzed by the lipases tested (Jaeger et al. [@CR40]).

### Enzymatic degradation of PHA in vivo in wild-type bacteria {#Sec9}

Another attractive approach to obtain R-HAs from PHAs is the in vivo depolymerization. The process utilizes intracellularly located PHA depolymerases for hydrolysis of PHAs (Foster et al. [@CR20]; Foster et al. [@CR21]; Jendrossek and Handrick [@CR41]). It has been efficiently accomplished with natural PHB-synthesizing bacteria to produce R-3HB with a yield of 96% (g R-3HB/g PHB) (Lee et al. [@CR58]). Appropriate environmental conditions are crucial for this process. Lee et al. ([@CR58]) reported that, with *Alcaligenes latus* (reclassified as *Azohydrogenomonas lata* (Xie and Yokota [@CR129])), lowering the environmental pH to 3--4 resulted in the highest activity of intracellular PHB depolymerase and blocked the reutilization of R-3HB by the cells.

In order to gain access to more interesting molecules, in vivo depolymerization of mcl-PHA in *P. putida* has been studied (Ren et al. [@CR89]; Ren Zulian et al. [@CR90]; Ruth et al. [@CR94]). PHA containing *P. putida* cells were suspended in phosphate buffer at different pH values. At more alkaline pH values (pH 9--11), the degradation of PHA and thus, the release of R-HA monomers were at their best (Ren et al. [@CR89]; Wang et al. [@CR125]). Under such conditions, PHAs containing *R*-3-hydroxyoctanoic acid (R-3HO) and R-3HHx were degraded with an efficiency of over 90% (w/w) in 9 h, and the yields of the corresponding monomers were also over 90% (w/w). Under the same conditions, unsaturated monomers *R*-3-hydroxy-6-heptenoic acid, *R*-3-hydroxy-8-nonenoic acid, and 3-hydroxy-10-undecenoic acid were also produced, although with a lower yield compared with the saturated monomers (Ren et al. [@CR89]).

It seems that PHB depolymerase of *A. latus* and mcl-PHA depolymerase of *P. putida* need different pH values to have the optimal activities to degrade PHA in vivo: the former at acidic conditions (pH 3--4) and the latter at alkaline conditions (pH 9--11) (Lee et al. [@CR58]; Ren et al. [@CR89]). In vitro, all of the so-far characterized PHB depolymerases and mcl-PHA depolymerase of *P. putida* exhibit optimal activities at the alkaline range (de Eugenio et al. [@CR15]; Jendrossek and Handrick [@CR41]). The requirement for different pH values could be caused by the difference between the intrinsic properties of the PHB depolymerase of *A. latus* from those of so-far analyzed depolymerases*.* However, this assumption needs to be verified by further investigation.

### R-HA production by metabolic pathway engineering {#Sec10}

Metabolic engineering is a powerful tool to solve defined biotechnological problems, such as enhancing intermediate concentrations or broadening the range of precursors. Vollbrecht et al. have reported to use a double mutant of *Ralstonia eutropha* (*Hydrogenomonas eutropha, Alcaligenes eutropha, Wautersia eutropha, Cupriavidus necator*)*,* which is unable to synthesize PHB and to utilize 3-hydroxybutanoate as a substrate, to produce R-3HB (Vollbrecht et al. [@CR123]; Vollbrecht and Schlegel [@CR121], [@CR122]). About 3.4 g/L of R-3HB was produced under optimum conditions (Vollbrecht and Schlegel [@CR122]). There have been several reports on metabolic engineering of *Escherichia coli* for the production of R-3HB (Lee and Lee [@CR56]; Park et al. [@CR86]). When recombinant *E. coli* carrying the *R. eutropha* PHB synthetic genes (β-ketothiolase (*phaA*), acetoacetyl-CoA reductase (*phaB*) and PHB synthetase (*phaC*)), and the depolymerase gene (*phaZ*) was cultivated in medium-containing glucose, R-3HB was produced (Lee and Lee [@CR56]). By integration of the PHB biosynthetic genes into the chromosome of *E. coli* together with providing a plasmid containing *phaZ*, R-3HB could be efficiently produced without plasmid instability in the absence of antibiotics (Lee and Lee [@CR56]).

It was also reported that R-HAs can be produced by recombinant organisms directly, without going through the PHA hydrolysis process (Chen and Wu [@CR9]; Gao et al. [@CR22]; Zhao et al. [@CR136]). For example, recombinant *E. coli* HB101 harboring PHB precursor genes *phaA* and *phaB* of *R. eutropha* was able to produce more than 1 g/L of 3HB monomer extracellularly after 48 h of fermentation (Wu et al. [@CR128]). Heterologous expression of (*R*)-3-hydroxydecanol-ACP:CoA transacylase gene (*phaG*) of *P. putida* in *E. coli* HB101 led to extracellular production of 3-hydroxydecanoic acid (3HD) from fructose with a yield of 0.587 g/L. Simultaneous expression of both *phaG* and *tesB* (encoding thioesterase II of *E. coli*) in *E. coli* HB101 increased 3HD production compared with the expression of *phaG* alone under identical conditions (Zheng et al. [@CR138]). Recently, TesB was found to be able to facilitate 3HB production (Liu et al. [@CR65]). *E. coli* BW25113 harboring *phaA*, *phaB*, and *tesB* genes produced approximately 4 g/L 3HB in shake flask culture within 24 h with glucose as a carbon source (Zheng et al. [@CR138]). The produced HAs mentioned here were not analyzed for their chiral configuration. However, due to the enzymatic activities of PhaB and PhaG, the obtained HAs are very likely to be R-HAs.

A biosynthetic pathway for the production of (*S*)-3-hydroxybutyric acid (S-3HB) from glucose was established in recombinant *E. coli* by introducing *phaA* from *R. eutropha*, the (*S*)-3-hydroxybutyryl-CoA dehydrogenase gene from *R. eutropha*, or *Clostridium acetobutylicum* ATCC824, and the 3-hydroxyisobutyryl-CoA hydrolase gene from *Bacillus cereus* ATCC14579 (Lee et al. [@CR60]). The recombinant *E. coli* could synthesize enantiomerically pure S-3HB in a concentration up to 10.3 g/L; the S-3HB productivity was 0.21 g/L/h. It was also reported that the chirality of 3HB could be controlled by metabolic pathway engineering of *E. coli* strains (Tseng et al. [@CR118]).The engineered strain achieved titers of enantiopure R-3HB and S-3HB as high as 2.92 h/L and 2.08 g/L, respectively, in shake flask cultures within 2 days (Tseng et al. [@CR118]).

1,3-Propanediol dehydrogenase (DhaT) and aldehyde dehydrogenase (AldD) from *P. putida* KT2442 are capable of transforming 1,4-butanediol (1,4-BD) to 4-hydroxybutyrate (4HB) (Zhang et al. [@CR134]). Thus, *Aeromonas hydrophila* 4AK4, *E. coli* S17-1, or *P. putida* KT2442 harboring *dhaT* and *aldD* were used to produce 4HB. Recombinant *A. hydrophila* 4AK4 containing *dhaT* and *aldD* was able to produce over 10 g/L 4HB from 20 g/L 1,4-BD after 52 h of cultivation in a 6-L fermenter (Zhang et al. [@CR134]). Recently, an economical, high-titer method for the production of 4-hydroxyvalerate (4HV) and 3-hydroxyvalerate (3HV) from the inexpensive and renewable carbon source levulinic acid was developed (Martin and Prather [@CR71]). These hydroxyvalerates were produced by periodically feeding levulinate to *P. putida* KT2440 expressing the *tesB* gene from *E. coli*.

Sandoval et al. ([@CR95]) reported that 3-hydroxy-*n*-phenylalkanoic acids can be produced by a genetically engineered strain of *P. putida* U. Overexpression of the gene encoding the poly(3-hydroxy-*n*-phenylalkanoate) (PHPhA) depolymerase (*phaZ*) in *P. putida* U avoids the accumulation of these polymers as storage granules. The genetically engineered strain of *P. putida* U (*ΔfadBA*; *phaZ* on plasmid) can efficiently convert different *n*-phenylalkanoic acids into their corresponding 3-hydroxy-*n*-phenylalkanoic acids derivatives, and it excretes these compounds into the culture broth. However, the obtained 3-hydroxy-*n*-phenylalkanoic acids are racemic mixtures (Sandoval et al. [@CR95]).

Medium chain length R-3HHx and R-3HO were produced by overexpressing the PHA depolymerase gene (*phaZ*) of *P. putida* KT2442, together with the putative long-chain fatty acid transport gene (*fadL*) of *P. putida* KT2442 and acyl-CoA synthetase gene (*fadD*) of *E. coli* MG1655 in *P. putida* KT2442 (Yuan et al. [@CR132]). In a 48-h fed-batch fermentation process conducted in a 6-L fermenter with 3-L sodium octanoate mineral medium, 5.8 g/L of extracellular R-3HHx and R-3HO was obtained in the fermentation broth (Yuan et al. [@CR132]). *P. putida* KTOY01, a PHA synthesis operon knockout mutant, was used for the direct production of medium chain length R-HAs without going through PHA synthesis (Chung et al. [@CR12]). R-3HHx, R-3HO, R-3HD, and (*R*)-3-hydroxydodecanoate (R-3HDD) were produced by *P. putida* KTOY01 carrying *tesB* using dodecanoate as a sole carbon source.

Potential applications of R-HAs {#Sec11}
===============================

Since R-HAs contain a chiral center and two easily modified functional groups (--OH and --COOH), they are valuable synthons, i.e., they may serve as starting materials for the synthesis of fine chemicals such as antibiotics, vitamins, flavors, fragrances, and pheromones (Chiba and Nakai [@CR11]; Ohashi and Hasegawa [@CR83]; Seebach et al. [@CR103]).

Chiral synthons for organic synthesis {#Sec12}
-------------------------------------

As R-HAs are not readily available on the market and their classical synthesis is rather tedious, only few synthetic routes using such reactants as starting material have been reported. The α,β-unsaturated δ-lactone (*R*)-massoialactone has been known as a constituent of natural medicine for many centuries and has been isolated from *Cryptocarya massoia*, as well as from jasmine flowers (Kaiser and Lamparsky [@CR42]). Like many aliphatic δ-lactones it occurs in several food flavors and essential oils, which are widely used due to their specific odor impression and low-threshold concentration. Touati et al. succeeded with the synthesis of massoialactone using a ruthenium-arylphosphine catalyst \[RuBr~2~((R)-SYNPHOS)\] to produce the intermediate (*R*)-3-hydroxyoctanoate through asymmetric hydrogenation (Touati et al. [@CR117]). Chiral synthesis of another δ-lactone, 3,5-dihydroxydecanoic acid, *via* (*R*)-3-hydroxyoctanoate has also been reported (Satō [@CR97]). Both syntheses use rather expensive complex metal catalysis to introduce the chiral center. Hence, easy accessibility of R-HAs would simplify these two and many other syntheses of saturated and unsaturated aliphatic β-lactones, which are interesting bioactive natural products.

Gloeosporone, containing a 14-membered macrolide, is an autoinhibitor of spore germination, and (*R*)-3-hydroxyoctanoate methyl ester can be used as reactant in its synthesis (Schreiber et al. [@CR100]). In this multistage synthesis, the method of choice for producing this compound is an asymmetric reduction of β-keto esters to cope with stereochemical problems. A Ru(II)-BINAP catalyst has been developed for introducing the proper chiral conformation (Noyori et al. [@CR80]). Challenging metal-catalyzed reactions can be avoided when starting with (*R*)-3-hydroxyoctanoate from a bacterial source.

Certain divinyl ether fatty acids inhibit mycelial growth and spore germination in certain fungi (Graner et al. [@CR26]). R-HAs can serve as chiral precursors for the synthesis of those compounds, e.g., (*R*)-3-hydroxyheptanoate was reported to be obtained by several crystallization steps from carcinogenic carbon tetrachloride for this purpose (Hamberg [@CR28]).

Linear-condensed triquinane sesquiterpenes are constituents of essential oils in plants and of great economical interest. Starting materials such as bicyclo\[3.2.0\]hept-3-en-6-ones (Marotta et al. [@CR68]) or tetrahydro-2*H*-cyclopenta\[*b*\]furan-2-ones (Marotta et al. [@CR70]) can be synthesized with (*R*)-3-hydroxyhept-6-enoate as reactant. (*R*)-3-hydroxyhept-6-enoate is also a precursor for eremophilan carbolactones (Hayakawa et al. [@CR33]), which are valuable compounds for drug synthesis and also known in traditional Chinese medicine. These compounds have been shown to have positive effects on blood circulation and rheumatism and some were found to exhibit antimicrobial activities (Zhang et al. [@CR133]).

In fact, there are many bioactive and pharmaceutically interesting molecules known containing R-HAs as sub-structures. Hence, the accessibility of these chiral acids as building blocks might open new synthetic routes towards such important compounds. Table [1](#Tab1){ref-type="table"} illustrates the versatility of possible applications using R-HAs. In Table [1](#Tab1){ref-type="table"}, only R-HAs directly involved in the subsequent reactions have been considered. Taking all possible biotechnologically producible R-HAs into account, the number of potential synthetic pathways towards pharmaceutically interesting compounds increases enormously. Table 1Potential applications for selected R-HAs as synthonsR-HAsPotential synthon forReference(*R*)-3-hydroxyundec-10-enoateInhibitor of cholesterol synthesis, effects 3-hydroxy-3-methyl-glutaryl (HMG) CoA synthetaseDirat et al. ([@CR18])Precursor of L-659,699 (inhibitor of cholesterol biosynthesis)Chiang et al. ([@CR10])(*R*)-3-hydroxy-undecanoateDepsipeptides (antibiotic/antifungal)Nihei et al. ([@CR79]); Wohlrab et al. ([@CR126])(−)-tetrahydrolipstatin (anti-obesity drug)Pons and Kocienski ([@CR88]); Sarabia and Chammaa ([@CR96])Lipid A mimic (immunobiological)Martin et al. ([@CR72])Stevastelins B and B3Sarabia and Chammaa ([@CR96])Sulfobacin AGupta et al. ([@CR27]); Irako and Shioiri ([@CR38]); Labeeuw et al. ([@CR54])Globomycin (antibiotic, signal peptidase II inhibitor)Kiho et al. ([@CR47]); Kiho et al. ([@CR48], [@CR49])PseudomycinRodriguez et al. ([@CR92])Topostins B567 and D654Irako and Shioiri ([@CR38])(*R*)-3-hydroxy-nonanoateGlobomycin analogs (antibiotic)Kiho et al. ([@CR49])(*R*)-2-benzylcyclohexanone (precursor of natural products)Katoh et al. ([@CR45])(*R*)-3-hydroxyoctanoateSimvastatin (antihypercholesterolemic, inhibitor of HMG-CoA reductaseLee and Lee ([@CR57]); Morgan and Burk ([@CR74])ViscosinHiramoto (1971)(*R*)-3-hydroxyhept-6-enoatePotent HMG CoA reductase inhibitor FR901512Inoue and Nakada ([@CR37])Rosuvastatin calcium, a HMG CoA reductase inhibitorsZlicar ([@CR139])α,β-disubstituted β-lactonesWu and Sun ([@CR127])Sphingofungin D (antifungal)Mori and Otaka ([@CR75]); Vanmiddlesworth et al. ([@CR120])Sphingofungin F (antifungal)Kobayashi et al. ([@CR52])Precursor of β-lactams for synthesis of carbacephems (class of antibiotics)Crocker and Miller ([@CR14])Ebelactone A and B (β-lactone enzyme inhibitor)Paterson and Hulme ([@CR87])BicycloheptenonesMarotta et al. ([@CR69])Cyclosporine A derivatives (immunosuppressive)Aebi et al. ([@CR1]); Colucci et al. ([@CR13]); Lynch et al. ([@CR67]); Rich et al. ([@CR91]); Schmidt and Siegel ([@CR99]); Schreiber et al. ([@CR100])(*S*)-citronellolHirama et al. ([@CR34])(*R*)-3-hydroxyheptanoateAnachelin (siderophore of *Anabaena cylindrica*)Ito et al. ([@CR39])Pravastatin (atherosclerosis/hypercholesteremia agent)Keri et al. ([@CR46])(*R*)-3-hydroxyhexanoateAnalogs of laulimalide (paclitaxel like antimicrotubule agent)Faveau et al. ([@CR19])

Homopolymers and tailor-made block copolymers {#Sec13}
---------------------------------------------

A special application of chiral 3HA is the possibility to create tailor-made polymers when using them as monomers in a condensation reaction. As in most polyester syntheses, the challenge is to reach high molecular weights. Various methods can be applied to condense R-HAs, in order to build up polyesters. Crucial features of those reactions are the activation of the carboxylic group and the removal of water to shift the equilibrium to the polyester product side. R-HAs can be activated by dicyclohexylcarbodiimide (DCC), *p*-toluenesulfonyl chloride (TosCl), or 2,4,6-triisopropylbenzenesulfonyl chloride (TPS) in anhydrous solvents at 25 °C to start the polymerization reaction (Hattori et al. [@CR32]). Triethyl amine (NEt~3~) has already been described to trigger polymerization of HA at 0 °C (Arslan et al. [@CR2]). Boiling HCl or concentrated H~2~SO~4~ can also be used to catalyze the release of water (Becker et al. [@CR3]). For conversion via titanium(IV) isopropoxide, a temperature of 140 °C and reduced pressure are necessary (Kobayashi and Hori [@CR51]). Seebach et al. obtained PHB from its monomers by adding COCl~2~ and pyridine at −78 °C (Lengweiler et al. [@CR62]; Seebach and Fritz [@CR102]). So far, only racemic starting materials or R-3HB have been used for the above described reactions.

Zhang et al. ([@CR134]) recently reported that R-4HB could be produced by recombinant bacteria harboring *dhaT* and *aldD* from 1,4-butanediol. Fermentation broth containing 4HB was further used for production of homopolymer poly(4-hydroxybutyrate) \[P(4HB)\] and copolymers poly(3-hydroxybutyrate-co-4-hydroxybutyrate) \[P(3HB-4HB)\] by recombinant *E. coli* S17-1 or *R. eutropha* H16 (Zhang et al. [@CR134]).

Since (*R*)-3-hydroxycarboxylic acids from bacterial sources have 100% (*R*)-configuration, they always result in polyesters composed of isotactic macromolecules. The process of in vivo depolymerization of PHA to obtain R-HAs and their consecutive polymerization might seem circuitous. However, it may open a new way to the synthesis of a totally isotactic class of homo-polyesters with special characteristics and unique properties, especially considering that PHAs synthesized in bacteria are always co-polyesters, with the exception of PHB and poly(3-hydroxyphenylvalerate). It is also feasible to synthesize block or graft copolymers using several types of different 3-hydroxycarboxylic acids as monomeric building blocks.

Synthesis of β-amino acids {#Sec14}
--------------------------

Park et al. ([@CR85]) have reported previously that optically active ethyl β-aminobutyrate can be prepared from R-HA. Ethyl R-3HB was treated with *p*-toluenesulfonyl chloride and sodium azide, leading to the formation of the corresponding azido ester, which was then converted to the β-amino acid by indium-mediated reduction. The overall reaction proceeded with inversion of configuration. This methodology is also expected to be applicable to the preparation of primary amines from the corresponding alcohols (Park et al. [@CR85]). Peptides containing β-amino acids are generally more stable to enzymatic hydrolysis due to the inability of proteases and peptidases to cleave the amide bonds adjacent to the β-amino acid (Park et al. [@CR85]; Seebach et al. [@CR103]). Since β-peptides are stable towards peptidases, they can be used as scaffolds for peptide mimics (Chen and Wu [@CR9]). Certain β-peptides have antibacterial, antiproliferative, or hemolytic properties (Chen and Wu [@CR9]).

Medical applications {#Sec15}
--------------------

It is known that R-3HB is ubiquitous in all kinds of cells (Chen [@CR7]). Thus, one of the biggest advantages for R-3HB is that it is well-tolerated by humans, i.e., it is biocompatible. Recently, R-3HB has been employed to treat traumatic injuries such as hemorrhagic shock, extensive burns, myocardial damage, and cerebral hypoxia, anoxia, and ischemia (Massieu et al. [@CR73]; Tieu et al. [@CR116]; Zou et al. [@CR140]). It was also shown that 3HB oligomers provide energy and show good penetration and rapid diffusion in peripheral tissue; hence, they could be an energy substrate for injured patients (Tasaki et al. [@CR114]). R-3HB could also serve as energy substrate in increasing cardiac efficiency and thus, prevents brain damage (Kashiwaya et al. [@CR43]). There is also evidence that R-3HB can correct defects in mitochondrial energy generation in the heart (Katayama et al. [@CR44]).

Furthermore, R-3HB has been found to be able to reduce the death rate of the human neuronal cell model culture for Alzheimer's and Parkinson's diseases and to ameliorate the appearance of corneal epithelial erosion through suppression of apoptosis (Kashiwaya et al. [@CR43]); R-3HB methyl ester was also found to dramatically improve the memory of mice (Zou et al. [@CR140]).

Recently, R-3HB was clearly demonstrated to have a positive effect on the growth of osteoblasts in vitro and an anti-osteoporosis effect in vivo (Zhao et al. [@CR137]). It was found that R-3HB increased serum alkaline phosphatase activity and calcium deposition, decreased serum osteocalcin, prevented bone mineral density reduction resulting from ovariectomization, leading to enhanced femur maximal load and bone deformation resistance, as well as improved trabecular bone volume (Zhao et al. [@CR137]).

Antimicrobial agents {#Sec16}
--------------------

Fatty acids have been known as antimicrobial agents for more than 80 years. They function as surface-active anionic detergents (Kodicek [@CR53]). Once the fatty acid has been adsorbed by cells, the inhibitory effect might be brought about by concomitant changes in cell permeability (Nieman [@CR78]). It has been reported that the length of the carbon chain plays an important role in the antimicrobial activity (Nieman [@CR78]). Some R-HAs exhibit antimicrobial or antiviral effects, while other R-HAs do not.

Sandoval et al. ([@CR95]) reported that (*R*)-3-hydroxy-*n*-phenylalkanoic acid can effectively attack *Listeria monocytogenes*, which is an ubiquitous microorganism, and able to multiply at refrigeration temperatures and is resistant to both high temperature and low pH. R-3HB has been shown to exhibit some antimicrobial, insecticidal, and antiviral activities (Chen and Wu [@CR9]; Shiraki et al. [@CR106]). Recently, Ruth et al. ([@CR94]) tested medium chain length R-HAs for their antimicrobial activities. It was found that R-3HO, (*R*)-3-hydroxy-8-nonenoic acid, and (*R*)-3-hydroxy-10-undecenoic acid exhibited much higher activities against the growth of *Listeria* species and *Staphylococcus aureus* than their racemic mixtures or their non-hydroxylated free fatty acid counterparts (Ruth et al. [@CR94]).

Biofuel {#Sec17}
-------

Recently, Zhang et al. ([@CR135]) proposed R-HA methyl esters (R-HAME) as a new type of biofuel. They found that the combustion heat of blended fuels, namely R-HAME---diesel or R-HAME---gasoline, were lower than that of pure diesel or gasoline but were usable as fuels. It was roughly estimated that the production costs of R-HAME-based biofuels from waste resources including waste water and activated sludge should be around US\$ 1,200/ton (Zhang et al. [@CR135]). It was claimed that R-HAME-based biofuel production from waste water or from activated sludge enjoys the advantages of waste water treatment accompanied by energy generation.

Perspectives of biotechnological production of R-HAs {#Sec18}
====================================================

For biotechnological production of R-HAs on a large scale, it is important to not only consider yield, product concentration, and productivity, but also the cost of substrates and downstream processing, which are crucial constraints for a process to become economically viable. Often a bioprocess optimized for production as established in academia does not necessarily represent the most favorable conditions when viewed from an economic standpoint. High substrate costs can abolish the advantage of high yield, or high purification cost can limit any cost advantages of an inexpensive carbon source. Clearly, these factors are interrelated.

At present, large research efforts have been dedicated to the use of lignocellulosic biomass. This is highly abundant and significantly cheaper than refined sugar, making it an interesting substrate for microbial production processes in general. PHAs have been reported to be produced from such biomass (Li et al. [@CR64]; Munoz and Riley [@CR76]; Yu and Chen [@CR130]; Yu and Stahl [@CR131]). However, one has to consider that lignocellulose comprises different types of substances that might interfere with the bioprocess and that require an extensive downstream processing, which would add to the final costs. Further investigations are needed to clarify these issues.

An integral part of process optimization must be the reduction of the purification costs, but these are highly interconnected with biological and economic factors. Purification costs are higher with less-purified substrates and by-products can also constitute an important problem. To ensure that minimum effort is required for purification, the preceding bioprocess should avoid accumulation of impurities as much as possible from the beginning of the process. Ruth et al. ([@CR94]) reported a biotechnological process to produce R-HAs. Here, chromatography was used to purify R-HAs. To be economically viable, further improvement of this process must be brought at the step of R-HA purification. Only under such a condition can this biotechnological process become attractive for industrial production of R-HAs.

To gain the most from the producing organism, the process must be optimized taking into account biological, as well as economic constraints. Viewing the bioprocess for R-HA production objectively, it appears that biomass accumulation somehow wastes the carbon source. Instead of being converted into PHAs (and subsequently R-HAs), the substrate is converted into biomass. A number of studies are therefore related to the idea of uncoupling biomass accumulation from PHA production (Sun et al. [@CR111]).

Very often there are problems that simply cannot be solved by the proper selection of the production organism and bioprocess engineering. The organisms themselves must be altered in a rational way to be able to cope with the constraints of cost-effective production. For example, lignocellulosic biomass is an attractive substrate for PHA/R-HA production. However, few microorganisms can metabolize pentose sugars derived from these raw materials (Lopes et al. [@CR66]; Tian et al. [@CR115]). Therefore, metabolic engineering of strains might enable the efficient utilization of this biomass. On the other hand, although the modification of defined pathways in an organism is usually straightforward, one should realize that only a few of these approaches have been successfully used in industrial applications. One of the reasons is exposure of the microorganisms to a variety of stresses. Stress requires the cell to dedicate more effort to maintaining its natural equilibrium. This greater effort leads to several consequences, including a change in metabolic activity, lower growth rate, lower viability, and lower productivity (Sauer et al. [@CR98]). Strain robustness, which is the ability of the microorganism to withstand the production environment, is therefore a key factor determining whether a bioprocess will be successful and industrially viable.

For a biotechnological process for R-HA production to be competitive at large scale, the following aspects have to be taken into account: substrate cost, product purification, and strain fitness. These aspects are interrelated, e.g., the choice of substrate cannot be made without considering downstream processing or strain fitness, the choice of strain influences downstream processing due to by-products and also influences the choice for substrates. Only when these aspects are properly addressed does the biotechnological process has the potential to be economically viable for industrial production of R-HAs. Once such processes are established, the applications of these chiral compounds in chemical and pharmaceutical industries will be possible.
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